# Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

> **NCT00238355** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Infection
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** caspofungin acetate
- **DRUG:** voriconazole

## Key facts

- **NCT ID:** NCT00238355
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** competing study at site
- **Last updated:** 2025-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238355, "Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00238355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*